| To: DewDiligence_on_SI who wrote (46) | 2/27/2024 6:30:33 PM | | From: BulbaMan | | | | I have VKTX in my portfolio at 15% but regrettably never got around to buying any in the real world.
Still, after all these years, it would be nice to win the Contest.;-)
(According to my spreadsheet at today's close my Contest portfolio is up an astounding 87%.)
Peace & good health,
Bulba |
| | 2024 Biotech Charity Contest | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: BulbaMan who wrote (47) | 2/27/2024 6:38:20 PM | | From: technetium | | | | I have a whopping sixteen sh of VKTX in my IRA, so it saw a bump today, but not enough to be dancing in the street. (That is sixteen as in sweet sixteen, not sixteen times any multiple other than one.)
20/20 hindsight is one thing. What I’d prefer is 20/20 foresight, or an accurate crystal ball. ;-)
It is 10% of my charity portfolio, so I expect it to move up. |
| | 2024 Biotech Charity Contest | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: technetium who wrote (45) | 2/27/2024 6:50:46 PM | | From: technetium | | | | VKTX offers “$350.0 million of shares of its common stock. Viking also intends to grant the underwriters a 30-day option to purchase up to an additional $52.5 million of shares of its common stock. All of the shares of common stock to be sold in the proposed offering are to be sold by Viking. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.”
Strike while the iron is hot. I’d read rumors that they might get bought out if results were good, but this amount of $ should keep them going solo for a while.
finance.yahoo.com |
| | 2024 Biotech Charity Contest | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: technetium who wrote (44) | 3/4/2024 11:35:07 AM | | From: technetium | | | | Well, March (and the last 4 days of this Leap Year February) roared in (out) like a lion. New records for the broader indices, the NASDAQ Composite Index up +1.7% for the week, and if the NASDAQ biotech index was sort of “meh” (+0.5%), the S&P biotech index, on the other hand boomed by +7.3% for the week, ending up +14% for YTD, outstripping the NASDAQ Composite's +8.4% YTD.
The big news for the week was the +$260% jump in VKTX, due to their announcement of positive Top-Line Results from a Phase 2 study of an anti-obesity drug (https://finance.yahoo.com/news/viking-therapeutics-announces-positive-top-120300339.html) to challenge the products of Lily and Novo Nordiisc, which triggered a ton of coverage in the financial press, and the announcement of a public offering of half a billion dollars worth at $85 a share, expected to close next Monday. VKTX has had a generally good year so far, yielding a YTD return of +350%, the number one selection in the contest.
Second place PYXS (+96% for the week), had a private placement to institutional investors worth $50 million, gross proceeds, at $4.78 a share, a discount of 27% of the weekly closing price. This resulted in a third place YTD return of +266%.
Third place CRDF jumped +84%, most of it on Friday after releasing Q4 and Annual financials that beat expectations.
Fourth place VINC (+64%) continued its rise from the previous week, again without any particular news, which allowed it to keep just ahead of PYXS as the number two issue in YTD returns, +267%.
And GTHX’s announcement of annual and Q4 earnings on Wednesday produced three days of general gains, and a fifth place in the weekly return of +50%.
On this week’s losing issues: bottom of the heap NERV (-69% of their initial price) had an FDA rejection of their schizophrenia drug, endorsing the agenda reviewers’ objections. Adding this to the previous week’s loss from the market’s treatment of their Q4/Annual financials, and now NERV is the second worst YTD performer (-57%).
The next four losers for the week were bad, but far from catastrophic. LRMR dropped -17%, which could be considered profit taking from the big jump of two week’s ago in response to a successful public offering, not enough to drop them from the top five YTD performers, +150%. KZIA was the fourth worst performer both for the week (-12%) and on the YTD list (-42%). And in the fifth worst spot, GRTS (-9.8%) announced a 40% reduction in workforce required by not receiving some expected external funding due to the delay in the initiation of a Phase 2b study.
If this was a good week for the S&P biotech index, it was a great week for the contestants, an average gain of +$14.5k, so that the YTD average portfolio is now +$30k in the black. Only one portfolio was in the red for the week, and that only by a loss of -$132.76, pushing the number of YTD profitable portfolios up to fourteen out of seventeen! That VKTX was selected by four different portfolios may have had something to do with this, those portfolios becoming the 1st, 2nd, 3rd and 5th top performers for the week. In first, BULBAMAN’s 15% bet on VKTX was responsible for almost the entirety of their weekly gain of $40k. In second RAJU_BIJLEE took a more conservative 10% position in VKTX, but received an additional boost by positive gains in every other of their choices for a net gain of +$37k. Both of them moved past ERIKOTTO to take the one-two positions in the YTD standings, (+$87k and +$74k) with a gap of $13k between the top two. (ERIKOTTO is only an additional $300 further behind). The remaining two VKTX holders, TECHNETIUM (+$32k) and DEW_DILIGENCE (+$24k) also improved their YTD positions by one place to fifth (+$54k) and seventh (+$35k) respectively.
Report Time Ranges
|
|
|
|
|
|
From
|
To
|
|
|
|
|
|
|
|
|
Recent
|
2/23/24
|
3/1/24
|
|
|
|
|
|
|
|
|
YTD
|
12/31/2023
|
|
|
|
|
Index Portfolios’ Performance
|
|
|
|
|
Symbol
|
Recent P/L
|
Recent %
|
YTD P/L
|
|
|
|
|
|
|
|
|
^IXIC
|
$1,852.72
|
1.7%
|
$8,417.55
|
|
|
|
|
|
|
|
|
^NBI
|
$563.95
|
0.5%
|
$3,309.31
|
|
|
|
|
|
|
|
|
^SPSIBI
|
$7,748.21
|
7.3%
|
$13,822.43
|
|
|
|
|
Share Performance
|
Recent Performance
|
YTD Performance
|
|
Top Five
|
|
Bottom Five
|
|
Top Five
|
|
Bottom 5
|
Symbol
|
P/L / Initial Price
|
Symbol
|
P/L / Initial Price
|
Symbol
|
YTD P/L / Initial Price
|
Symbol
|
YTD P/L/ Initial Price
|
VKTX
|
256.9%
|
NERV
|
-68.9%
|
VKTX
|
351.5%
|
CNSP
|
-75.6%
|
PYXS
|
96.1%
|
LRMR
|
-16.9%
|
VINC
|
266.9%
|
NERV
|
-57.2%
|
CRDF
|
83.8%
|
TERN
|
-12.6%
|
PYXS
|
266.1%
|
PACB
|
-47.1%
|
VINC
|
63.6%
|
KZIA
|
-11.6%
|
JSPR
|
179.8%
|
KZIA
|
-41.5%
|
GTHX
|
49.5%
|
GRTS
|
-9.8%
|
LRMR
|
149.5%
|
ONT.L
|
-37.9%
|
Average and Median Portfolio Performance
|
|
Recent P/L
|
|
|
|
YTD P/L
|
|
|
|
Avg.
|
Median
|
|
|
|
Avg
|
Median
|
|
|
|
$14,493.29
|
$12,116.18
|
TOMATO
|
|
$29,598.16
|
$24,652.53
|
TRACE I11
|
Top Seven Portfolio Performances
|
Top Recent Performers
|
Top YTD Performers
|
Contestant (Prev. Rank)
|
Recent P/L
|
P/L vs. ^SPSIBI
|
YTD P/L (Rank)
|
Contestant (Prev. Rank)
|
YTD P/L
|
vs. Top Portfolio
|
P/L vs. ^SPSIBI
|
Rec. P/L (Rank)
|
1 - BULBAMAN (11)
|
$40,154.45
|
$32,406.24
|
$86,882.00 (1)
|
1 - BULBAMAN (2)
|
$86,882.00
|
——
|
$73,059.57
|
$40,154.45 (1)
|
2 - RAJU_BIJLEE (2)
|
$36,807.38
|
$29,059.17
|
$73,891.88 (2)
|
2 - RAJU_BIJLEE (3)
|
$73,891.88
|
$12,990.12
|
$60,069.45
|
$36,807.38 (2)
|
3 - TECHNETIUM (3)
|
$31,641.96
|
$23,893.76
|
$54,515.98 (5)
|
3 - ERIKOTTO (1)
|
$73,581.66
|
$13,300.34
|
$59,759.23
|
$12,137.02 (8)
|
4 - BLADERUNNER (1)
|
$25,135.25
|
$17,387.04
|
$61,074.47 (4)
|
4 - BLADERUNNER (4)
|
$61,074.47
|
$25,807.53
|
$47,252.05
|
$25,135.25 (4)
|
5 - DEW_DILIGENCE (6)
|
$23,574.80
|
$15,826.59
|
$35,341.06 (7)
|
5 - TECHNETIUM (6)
|
$54,515.98
|
$32,366.02
|
$40,693.55
|
$31,641.96 (3)
|
6 - TRACE I11 (5)
|
$19,504.97
|
$11,756.76
|
$24,652.53 (9)
|
6 - TOMATO (5)
|
$44,580.53
|
$42,301.47
|
$30,758.10
|
$12,116.18 (9)
|
7 - ARTHUR RADLEY (16)
|
$12,382.81
|
$4,634.60
|
$20,256.81 (10)
|
7 - DEW_DILIGENCE (8)
|
$35,341.06
|
$51,540.94
|
$21,518.63
|
$23,574.80 (5)
|
8 - ERIKOTTO (13)
|
$12,137.02
|
$4,388.81
|
$73,581.66 (3)
|
8 - JR_95 (7)
|
$28,311.87
|
$58,570.13
|
$14,489.45
|
$9,008.22 (11)
|
Top Portfolios’ Contents
|
Second Place Recent Performance Portfolio (RAJU_BIJLEE)
|
Top YTD Performance Portfolio (BULBAMAN)
|
Symbol (Rank)
|
Initial Allocation
|
Value/Total | ROI
|
YTD Stock P/L
|
Recent Stock P/L
|
% Current Price Change for $1,000 P/L
|
Symbol (Rank)
|
Initial Allocation
|
Value/Total | ROI
|
YTD Stock P/L
|
Recent Stock P/L
|
% Current Price Change for $1,000 P/L
|
ALLO
|
10.00%
|
8.8% | 53.9%
|
$5,389.41
|
$1,246.11
|
6.5%
|
CU6.AX
|
20.00%
|
14.5% | 35.6%
|
$7,125.80
|
$954.33
|
3.7%
|
ALT
|
10.00%
|
6.2% | 7.5%
|
$746.67
|
$2,568.89
|
9.3%
|
CYTH
|
10.00%
|
5.4% | 1.3%
|
$125.79
|
-$880.50
|
9.9%
|
ARDX
|
10.00%
|
8.7% | 50.6%
|
$5,064.52
|
$1,064.52
|
6.6%
|
LRMR
|
10.00%
|
13.3% | 149.5%
|
$14,945.05
|
-$1,692.31
|
4.0%
|
CBUS
|
10.00%
|
5.3% | -8.4%
|
-$840.12
|
$147.66
|
10.9%
|
PMN
|
10.00%
|
9.7% | 81.7%
|
$8,173.91
|
$86.96
|
5.5%
|
GLYC
|
10.00%
|
7.3% | 27.5%
|
$2,754.24
|
$466.10
|
7.8%
|
SNGX
|
10.00%
|
5.4% | 0.8%
|
$78.95
|
-$13.16
|
9.9%
|
IMTX
|
10.00%
|
7.1% | 22.9%
|
$2,288.70
|
$683.76
|
8.1%
|
TCON
|
10.00%
|
5.7% | 7.4%
|
$736.72
|
$1,250.71
|
9.3%
|
IOVA
|
10.00%
|
11.9% | 106.5%
|
$10,651.91
|
$1,254.61
|
4.8%
|
TLX.AX
|
15.00%
|
9.1% | 13.4%
|
$2,006.90
|
$1,920.74
|
5.9%
|
OCUL
|
10.00%
|
13.9% | 141.0%
|
$14,103.14
|
$1,995.52
|
4.1%
|
VKTX
|
15.00%
|
36.8% | 357.9%
|
$53,688.88
|
$38,527.67
|
1.5%
|
RVNC
|
10.00%
|
4.6% | -20.6%
|
-$2,059.16
|
$1,695.11
|
12.6%
|
|
|
|
|
|
|
VKTX
|
10.00%
|
26.3% | 357.9%
|
$35,792.58
|
$25,685.12
|
2.2%
|
|
|
|
|
|
|
|
| | 2024 Biotech Charity Contest | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (2) |
|
| To: technetium who wrote (53) | 3/11/2024 12:24:00 PM | | From: Bladerunner17 | | | | CRDF: Change of opinion by "Seeking Alpha" analyst
Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)
Mar. 08, 2024 7:37 PM ET Cardiff Oncology, Inc. (CRDF) Stock 8 Comments2 Likes
Galzus Research
901 Followers
Follow
Summary- Cardiff Oncology is focused on developing a drug for colorectal cancer and pancreatic cancer, with promising early activity shown in colorectal cancer patients.
- The company is now focused on moving their drug to the first-line setting and has started a clinical trial to evaluate its efficacy.
- Cardiff Oncology has a strong financial position with enough funds to operate through Q3 2025, but the success of their drug is heavily dependent on the outcomes of a single trial.
Vladimir Vladimirov/E+ via Getty Images
Topline Summary and UpdateCardiff Oncology (NASDAQ: CRDF) is a cancer-focused biotech working on developing a drug that exploits a novel target, particularly in colorectal cancer. In my past articles, I have been lukewarm to slightly pessimistic about their findings presented to date and their overall outlook. But recent news has sent them on a meteoric rise, and the ensuing roller coaster has readers asking me directly for input on this company. So let's examine what happened to lead to this strong rise in value, as well as where I think they might be headed next.
Pipeline UpdatesOnvansertib
Today, the PLK1 inhibitor onvansertib remains the one and only drug in development by CRDF, meaning its entire future rests on the success or failure of this agent. It is being studied mainly in a few forms of gastrointestinal cancer, namely colorectal cancer and pancreatic cancer, both representing critical unmet needs in oncology.
Most of the focus I've given in my previous writings has been for the colorectal cancer program, which has demonstrated some encouraging (though early) activity in the setting of KRAS -mutant, metastatic disease. Updated findings using add-on onvansertib with FOLFIRI-bevacizumab in the second-line setting have since been published in Clinical Cancer Research, showing a 44% response rate among 18 patients, with reasonable toxicity.
Now, the company's focus is on moving onvansertib to the first-line setting, hurdling over the typical path we have taken in targeted therapy development of starting with more "dire" clinical settings, establishing efficacy, and then moving them up. The phase 2 CRDF-004 study is seeking to randomize 90 patients with newly diagnosed, metastatic, KRAS or NRAS mutated CRC to receive first-line doublet chemotherapy plus bevacizumab, with or without one of 2 doses of onvansertib. The primary endpoint is objective response rate. CRDF announced that the first patient was dosed in this study on leap day. Initial top-line findings are anticipated later this year.
The phase 2 ONSEMBLE second-line study has been discontinued to focus on the frontline study, but CRDF provided an update in their most recent guidance that they interpret as evidence that patients who had no prior bevacizumab seemed to have better response rates, as high as 50%. It is worth keeping in mind that the patient numbers are small here, and in the standard of care, most patients with KRAS mutated mCRC are going to receive bevacizumab as part of their care, so it's difficult to interpret these findings with any real de
We've also gotten glimpses of clinical development for onvansertib in non-CRC settings. Most notably, a report of activity back in September suggests preliminary benefit from onvansertib in metastatic pancreatic cancer and extensive-stage small cell lung cancer. In particular, 4 of 21 patients with pancreatic cancer treated with add-on onvansertib (plus nal-IRI and 5-FU) yielding a 19% objective response rate, which tracks favorably with the findings from NAPOLI-1. A single response was observed with onvansertib monotherapy in the 7 patients with SCLC.
Financial OverviewAs of their most recent earnings report, CRDF held $77.4 million in total current assets, including $21.7 million in cash and equivalents, and another $53.2 million in short-term investments. Their reported annual loss was $45.4 million, with a recognized net loss of $41.4 million after interest income and other expenses.
Given these expenses, CRDF has upwards of 2 years of cash and assets on hand to fund activities, with a serious going concern emerging about a year from now at the current burn rate, by my estimation. This is consistent with guidance from the company saying they have funds to operate through Q3 2025.
Strengths and RisksStrength - CRDF's fiscal management focuses on high-priority studies
For a company in the middle of developing a drug, CRDF has a rather low cash burn rate. This could help give them time to get a data readout that propels them to the levels that we've seen recently with the likes of Janux Therapeutics, where relatively small numbers rev up a huge cash raise. Such penny-pinching stewardship is admirable, although there is a catch
Risk - Careful prioritization places most eggs in one basket
CRDF is now resting almost everything on the CRDF-004 study, and this trial is taking a risky step moving things into the frontline setting. Despite it being at the FDA's recommendation (according to the company), the observation in their 2 early studies that bevacizumab-naive patients seemed to derive the most benefit from onvansertib is shaky to me. These are small patient numbers, and I don't feel this is a hypothesis that's been carried through rigorously enough at this point.
That doesn't mean I think they're wrong, and I don't think it's a wantonly reckless step to go first line. If onvansertib really does work best in bev-naive patients, then this should end up being the exact play they need to make. But it's based on an idea that comes from pretty small patient numbers, and CRDF-004 may not generate convincing-enough findings to really show that onvansertib is moving the needle. All investors should be aware of that risk before jumping in.
Bottom-Line Summary: Why the Rating Change?As of late, developmental biotech companies are undergoing a surge of interest, with multiple companies showing promising phase 1 data sending them into market caps of billions. I do not think this is necessarily justified, but it speaks to the power of encouraging early data. CRDF, even after its recent gains, has the opportunity to surge even higher if their anticipated mid-2024 data readout in CRC shows support for their idea that onvansertib has more benefit in patients with no exposure to bevacizumab (which would be true of all first-line patients).
Tackling KRAS would be a huge coup, since there are currently no approved therapies that are specifically beneficial for patients in the frontline setting of mCRC with KRAS mutations. It's only used right now to help determine what therapies patients should not receive.
All said, I'm upgrading my rating to a "strong buy," which means that I think you should take a serious look at their portfolio and consider entering into a limited position. I would warn heavily against overextending, though, since so much of the company's value is now going to be tied to the outcomes of a single trial, and a lot can go wrong there. But it is clear now that the ceiling is too high to ignore for this company.
This article was written by
Galzus Research
901 Followers
Follow
I have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of investing in this space. |
| | 2024 Biotech Charity Contest | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: technetium who wrote (53) | 3/14/2024 6:37:47 PM | | From: technetium | | | | Last week, I neglected to note that Pfizer had paid out a dividend of $0.42 a share on March 1, Friday of the previous week, which was reinvested in the stock using the Friday closing price ($26.59) as the purchase price for the additional shares. As a result JACK HARTMANN earned an additional $145.88.
I also discovered an error in the calculation for the YTD P/L of VKTX: The correct value is +357.9% rather than the +$351.5% given. This value was not used in the calculation of any portfolio results, so the other results in the report are unchanged.
The delay in this week was to correctly get the dividend calculation, and discovered a slight miscalculation in the “recent” performance for one (and only one) portfolio.
So here is the raw results. Not a good week, but a lot of mix up in the standings. Special congrats to TRACE I11, the only portfolio with a position in VINC (but only 5% of the initial portfolio alas). VKTX gave up some progress so the winners of last week didn’t keep their places in the YTD standings, except DEW_DILIGENCE.
AMGN had a dividend paid on Friday. But only NOTABOT had a position.
Report Time Ranges
|
|
|
|
|
| From
| To
|
|
|
|
|
|
|
|
| Recent
| 3/1/24
| 3/8/2024
|
|
|
|
|
|
|
|
| YTD
| 12/31/2023
|
|
|
|
| Index Portfolios’ Performance
|
|
|
|
| Symbol
| Recent P/L
| Recent %
| YTD P/L
|
|
|
|
|
|
|
|
| ^IXIC
| -$1,264.56
| -1.2%
| $7,152.99
|
|
|
|
|
|
|
|
| ^NBI
| -$1,256.49
| -1.2%
| $2,052.81
|
|
|
|
|
|
|
|
| ^SPSIBI
| -$2,994.26
| -2.6%
| $10,828.17
|
|
|
|
| Share Performance
| Recent Performance
| YTD Performance
|
| Top Five
|
| Bottom Five
|
| Top Five
|
| Bottom 5
| Symbol
| P/L / Initial Price
| Symbol
| P/L / Initial Price
| Symbol
| YTD P/L / Initial Price
| Symbol
| YTD P/L/ Initial Price
| VINC
| 304.2%
| AMLX
| -104.3%
| VINC
| 571.2%
| AMLX
| -77.2%
| APGE
| 108.4%
| VKTX
| -72.2%
| VKTX
| 285.7%
| CNSP
| -66.1%
| CRDF
| 83.1%
| PYXS
| -53.3%
| JSPR
| 249.2%
| PACB
| -54.8%
| JSPR
| 69.3%
| TARA
| -42.7%
| PYXS
| 212.8%
| NERV
| -54.5%
| SYRE
| 37.3%
| EYEN
| -38.0%
| CRDF
| 179.7%
| KZIA
| -52.8%
| Average and Median Portfolio Performance
|
| Recent P/L
|
|
|
| YTD P/L
|
|
|
| Avg.
| Median
|
|
|
| Avg
| Median
|
|
|
| -$3,611.29
| -$3,218.73
| ALONER
|
| $25,995.45
| $17,940.73
| JACK HARTMANN
| Top Seven Portfolio Performances
| Top Recent Performers
| Top YTD Performers
| Contestant (Prev. Rank)
| Recent P/L
| P/L vs. ^SPSIBI
| YTD P/L (Rank)
| Contestant (Prev. Rank)
| YTD P/L
| vs. Top Portfolio
| P/L vs. ^SPSIBI
| Rec. P/L (Rank)
| 1 - BLADERUNNER (4)
| $21,644.81
| $24,639.07
| $82,719.28 (1)
| 1 - BLADERUNNER (4)
| $82,719.28
| ——
| $71,891.11
| $21,644.81 (1)
| 2 - JACK HARTMANN (12)
| $12,942.26
| $15,936.52
| $17,940.73 (9)
| 2 - BULBAMAN (1)
| $77,204.98
| $5,514.30
| $66,376.81
| -$9,677.02 (12)
| 3 - TRACE I11 (6)
| $12,281.99
| $15,276.25
| $36,934.52 (6)
| 3 - ERIKOTTO (3)
| $60,085.12
| $22,634.16
| $49,256.96
| -$13,496.53 (14)
| 4 - DART LANZER (15)
| $2,607.67
| $5,601.93
| $1,361.15 (14)
| 4 - RAJU_BIJLEE (2)
| $60,010.05
| $22,709.23
| $49,181.89
| -$13,881.82 (15)
| 5 - A. J. MULLEN (17)
| $1,881.68
| $4,875.94
| -$12,183.30 (17)
| 5 - TOMATO (6)
| $42,499.83
| $40,219.45
| $31,671.67
| -$2,080.69 (7)
| 6 - KATHLEEN (14)
| -$307.49
| $2,686.77
| $1,639.88 (13)
| 6 - TRACE I11 (9)
| $36,934.52
| $45,784.76
| $26,106.35
| $12,281.99 (3)
| 7 - TOMATO (9)
| -$2,080.69
| $913.57
| $42,499.83 (5)
| 7 - DEW_DILIGENCE (7)
| $28,237.39
| $54,481.89
| $17,409.22
| -$7,103.67 (11)
| 8 - NOTABOT (13)
| -$2,239.45
| $754.81
| -$662.05 (15)
| 8 - TECHNETIUM (5)
| $27,767.15
| $54,952.13
| $16,938.98
| -$26,748.83 (17)
| Top Portfolios’ Contents
| Second Place Recent Performance Portfolio (JACK HARTMANN)
| Top YTD Performance Portfolio (BLADERUNNER)
| Symbol (Rank)
| Initial Allocation
| Value/Total | ROI
| YTD Stock P/L
| Recent Stock P/L
| % Current Price Change for $1,000 P/L
| Symbol (Rank)
| Initial Allocation
| Value/Total | ROI
| YTD Stock P/L
| Recent Stock P/L
| % Current Price Change for $1,000 P/L
| APGE
| 10.00%
| 20.5% | 141.7%
| $14,173.23
| $10,844.67
| 4.1%
| BCAB
| 10.00%
| 6.2% | 12.6%
| $1,260.16
| -$325.20
| 8.9%
| ARWR
| 10.00%
| 9.3% | 9.3%
| $931.37
| -$859.48
| 9.1%
| CRDF
| 20.00%
| 30.6% | 179.7%
| $35,945.95
| $16,621.62
| 1.8%
| AUPH
| 10.00%
| 5.1% | -39.6%
| -$3,959.96
| -$389.32
| 16.6%
| CRIS
| 10.00%
| 4.5% | -17.6%
| -$1,764.71
| $337.25
| 12.1%
| BNTX
| 10.00%
| 7.3% | -13.5%
| -$1,352.09
| $31.27
| 11.6%
| GLYC
| 10.00%
| 6.3% | 15.7%
| $1,567.80
| -$1,186.44
| 8.6%
| BRNS
| 10.00%
| 6.0% | -29.5%
| -$2,953.93
| -$948.51
| 14.2%
| IMMP
| 10.00%
| 6.3% | 14.6%
| $1,458.33
| $1,875.00
| 8.7%
| CMPS
| 10.00%
| 10.5% | 24.3%
| $2,434.29
| -$685.71
| 8.0%
| IOVA
| 20.00%
| 21.1% | 93.1%
| $18,622.39
| -$2,681.43
| 2.6%
| MRNA
| 10.00%
| 8.8% | 3.6%
| $359.98
| $801.41
| 9.7%
| JSPR
| 10.00%
| 19.1% | 249.2%
| $24,917.62
| $6,932.83
| 2.9%
| NVCR
| 10.00%
| 9.4% | 10.8%
| $1,078.37
| $194.24
| 9.0%
| REPL
| 10.00%
| 5.9% | 7.1%
| $711.74
| $71.17
| 9.3%
| PFE
| 10.00%
| 8.1% | -4.0%
| -$395.99
| $222.28
| 10.4%
|
|
|
|
|
|
| SYRE
| 10.00%
| 14.9% | 76.3%
| $7,625.46
| $3,731.41
| 5.7%
|
|
|
|
|
|
|
|
| | 2024 Biotech Charity Contest | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: technetium who wrote (55) | 3/19/2024 2:43:36 PM | | From: technetium | | | | Well if last week was a “not good” week, I guess this week deserves the whole “sad trombones” treatment, at least as far as the contest portfolios are concerned. The Broader market, i.e. the NASDAQ Composite gave up -0.7% for the week, an improvement over the previous week’s loss of -1.2%, but the biotech indices increased the magnitude of their losses, e.g. the S&P biotech composite went from -2.6% to -4.3%. The NASDAQ biotech index moved into negative territory for YTD returns.
Of course it wasn’t universally bad news. TCON was up +73% of its original price for the week, though not enough to put its YTD performance into the top five. It closed significantly below its peak return of an additional +150% at the end of Wednesday. The activity could be at best indirecly related to their 4th quarter results, exceeding expectations, released on the previous Wednesda (March 6), or the release of the investor's call transcript on Thursday (March 7).
CRDF was in second for the week, +60%, adding to the previous week’s gain of +83%, again several weeks after their 2023 earnings meeting expectations, moving it’s YTD performance from fifth to second (+240%).
SYRE, in third with (+35%) also continued its fifth place performance of the previous week (+37%). SLDB in fourth (+32%) at least had its annual/Q4 financials announced this week, as did fifth place LIFE (+28%), although on Saturday one analyst presented the annual earnings as a disappointment.
And as a sign of the general chaos of the last few weeks, the weeks big loser, VINC, dropped -200% of its original price, though this was after the dizzying +300% gain of the previous week, so that it still maintained its position at the top of the YTD performance, +370%. VKTX, the big winner of two weeks ago slid an additional -50% for this week, slipping below CRDF into third for YTD performance (+240%).
The biotech carnage resulted in the average portfolio losing -$5.8k for the week, so it should be no surprise that only two portfolios managed a profit. The good news at the end of February had produced a fairly fat cushion so that even now the average portfolio YTD (+$20k) is significantly outpacing the NASDAQ (+$6.4k) and thirteen out of seventeen portfolios are still in the black.
KATHLEEN was the number one for the week (+$1.5k), thanks to holdings of SLDB and LXRX. BLADERUNNER only had one holding in the black for the week, but it was a 20% position in CRDF, which earned $12k, though after the losing positions their net return was +$180, putting them in second for the week and enough to keep them at the top YTD spot (+$83k), and opening up their lead over BULBAMAN to $13k. JACK HARTMANN’s week’s loss, -$970, put them in third for the week, and returned them to the top YTD portfolios in eighth place (+$17k).
Report Time Ranges
|
|
|
|
|
| From
| To
|
|
|
|
|
|
|
|
| Recent
| 3/8/2024
| 3/15/2024
|
|
|
|
|
|
|
|
| YTD
| 12/31/2023
|
|
|
|
| Index Portfolios’ Performance
|
|
|
|
| Symbol
| Recent P/L
| Recent %
| YTD P/L
|
|
|
|
|
|
|
|
| ^IXIC
| -$745.70
| -0.7%
| $6,407.29
|
|
|
|
|
|
|
|
| ^NBI
| -$2,164.77
| -2.1%
| -$111.95
|
|
|
|
|
|
|
|
| ^SPSIBI
| -$4,811.61
| -4.3%
| $6,016.56
|
|
|
|
| Share Performance
| Recent Performance
| YTD Performance
|
| Top Five
|
| Bottom Five
|
| Top Five
|
| Bottom 5
| Symbol
| P/L / Initial Price
| Symbol
| P/L / Initial Price
| Symbol
| YTD P/L / Initial Price
| Symbol
| YTD P/L/ Initial Price
| TCON
| 73.1%
| VINC
| -198.3%
| VINC
| 372.9%
| AMLX
| -78.0%
| CRDF
| 60.1%
| VKTX
| -49.5%
| CRDF
| 239.9%
| CNSP
| -71.9%
| SYRE
| 34.6%
| TNYA
| -44.0%
| VKTX
| 236.2%
| PACB
| -61.4%
| SLDB
| 31.6%
| CCCC
| -36.6%
| JSPR
| 217.9%
| NERV
| -54.6%
| LIFE
| 28.4%
| LRMR
| -33.0%
| PYXS
| 184.4%
| KZIA
| -49.1%
| Average and Median Portfolio Performance
|
| Recent P/L
|
|
|
| YTD P/L
|
|
|
| Avg.
| Median
|
|
|
| Avg
| Median
|
|
|
| -$5,779.65
| -$5,584.11
| JR_95
|
| $20,215.80
| $16,610.18
| TECHNETIUM
| Top Seven Portfolio Performances
| Top Recent Performers
| Top YTD Performers
| Contestant (Prev. Rank)
| Recent P/L
| P/L vs. ^SPSIBI
| YTD P/L (Rank)
| Contestant (Prev. Rank)
| YTD P/L
| vs. Top Portfolio
| P/L vs. ^SPSIBI
| Rec. P/L (Rank)
| 1 - KATHLEEN (6)
| $1,478.36
| $6,289.97
| $3,118.24 (12)
| 1 - BLADERUNNER (1)
| $82,900.53
| ——
| $76,883.97
| $181.25 (2)
| 2 - BLADERUNNER (1)
| $181.25
| $4,992.86
| $82,900.53 (1)
| 2 - BULBAMAN (2)
| $70,297.72
| $12,602.82
| $64,281.16
| -$6,907.26 (11)
| 3 - JACK HARTMANN (2)
| -$969.28
| $3,842.33
| $16,971.45 (8)
| 3 - ERIKOTTO (3)
| $51,055.57
| $31,844.96
| $45,039.02
| -$9,029.55 (13)
| 4 - TOMATO (7)
| -$1,320.65
| $3,490.96
| $41,179.19 (5)
| 4 - RAJU_BIJLEE (4)
| $46,891.67
| $36,008.86
| $40,875.11
| -$13,118.38 (16)
| 5 - DART LANZER (4)
| -$2,453.06
| $2,358.54
| -$1,091.92 (14)
| 5 - TOMATO (5)
| $41,179.19
| $41,721.35
| $35,162.63
| -$1,320.65 (4)
| 6 - NOTABOT (8)
| -$2,888.88
| $1,922.73
| -$3,550.93 (15)
| 6 - TRACE I11 (6)
| $22,255.86
| $60,644.67
| $16,239.30
| -$14,678.66 (17)
| 7 - ARTHUR RADLEY (13)
| -$3,815.15
| $996.46
| $4,254.14 (11)
| 7 - DEW_DILIGENCE (7)
| $18,825.10
| $64,075.43
| $12,808.54
| -$9,412.29 (14)
| 8 - STEVE LOKNESS (10)
| -$4,116.52
| $695.09
| $1,446.18 (13)
| 8 - JACK HARTMANN (9)
| $16,971.45
| $65,929.08
| $10,954.89
| -$969.28 (3)
| Top Portfolios’ Contents
| Top Recent Performance Portfolio (KATHLEEN)
| Top YTD Performance Portfolio (BLADERUNNER)
| Symbol (Rank)
| Initial Allocation
| Value/Total | ROI
| YTD Stock P/L
| Recent Stock P/L
| % Current Price Change for $1,000 P/L
| Symbol (Rank)
| Initial Allocation
| Value/Total | ROI
| YTD Stock P/L
| Recent Stock P/L
| % Current Price Change for $1,000 P/L
| CNSP
| 10.00%
| 2.7% | -71.9%
| -$7,194.49
| -$579.53
| 35.6%
| BCAB
| 10.00%
| 5.4% | -0.8%
| -$81.30
| -$1,341.46
| 10.1%
| CRVS
| 10.00%
| 10.5% | 8.0%
| $795.45
| -$1,250.00
| 9.3%
| CRDF
| 20.00%
| 37.2% | 239.9%
| $47,972.97
| $12,027.03
| 1.5%
| ITRM
| 10.00%
| 7.2% | -25.9%
| -$2,588.83
| -$456.85
| 13.5%
| CRIS
| 10.00%
| 4.4% | -19.2%
| -$1,921.57
| -$156.86
| 12.4%
| LXRX
| 10.00%
| 16.5% | 69.9%
| $6,993.46
| $2,810.46
| 5.9%
| GLYC
| 10.00%
| 5.9% | 8.5%
| $847.46
| -$720.34
| 9.2%
| ONVO
| 10.00%
| 9.2% | -5.4%
| -$540.54
| $270.27
| 10.6%
| IMMP
| 10.00%
| 5.4% | -0.4%
| -$41.67
| -$1,500.00
| 10.0%
| PSTV
| 10.00%
| 9.6% | -1.1%
| -$114.29
| $228.57
| 10.1%
| IOVA
| 20.00%
| 18.7% | 71.1%
| $14,218.94
| -$4,403.44
| 2.9%
| SCYX
| 10.00%
| 6.3% | -35.0%
| -$3,497.76
| -$941.70
| 15.4%
| JSPR
| 10.00%
| 17.4% | 217.9%
| $21,787.07
| -$3,130.54
| 3.1%
| SLDB
| 10.00%
| 20.7% | 113.0%
| $11,302.93
| $3,159.61
| 4.7%
| REPL
| 10.00%
| 5.5% | 1.2%
| $118.62
| -$593.12
| 9.9%
| VERU
| 10.00%
| 7.8% | -19.4%
| -$1,944.44
| -$937.50
| 12.4%
|
|
|
|
|
|
| VERV
| 10.00%
| 9.6% | -0.9%
| -$93.26
| -$824.96
| 10.1%
|
|
|
|
|
|
|
|
| | 2024 Biotech Charity Contest | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| |
